 This is a Phase III, multicenter, open-label study that will be conducted at approximately 7-12 sites in the United States, Canada and Europe in pediatric patients with suboptimal LV EBD on non-contrast 2D transthoracic echocardiography with harmonic imaging. It is estimated that 92 patients will be enrolled to provide 73 evaluable patients. 